Is cholesterol a link between kidney and heart disease?
Each of the 11 major organ systems in the human body has a unique function that cooperates with the next to mediate homeostasis. These systems work together efficiently when a person is healthy; just think of how lightning-fast neural signals deliver cues from the brain to the muscles so you can move your hand off a hot stove. But, how do your systems affect one another in disease states? This is a question that researchers have begun to explore.
For example, researchers reported in 2004 that patients with chronic kidney disease, or CKD, were at an increased risk for cardiovascular disease, or CVD, with CVD being the leading cause of mortality in CKD patients. The kidneys filter waste from the blood, which is excreted as urine, and CKD is characterized by progressive loss of kidney function. The cardiovascular system pumps oxygenated blood to the organs and can be perturbed by diet, stress and other diseases, including CKD. But why would a patient with CKD be at an increased risk for CVD? How are these two systems related?

For more than 40 years now, researchers have demonstrated that low levels of high-density lipoprotein, or HDL —which carries low-density lipoprotein, or LDL, out of the arteries— is a risk factor for coronary heart disease, a type of CVD, in the general population. However, scientists know little about the mechanistic role of HDL cholesterol in CVD onset in CKD patients.
Baohai Shao from the University of Washington, Subramaniam Pennathur from the University of Michigan, and a team of researchers recently published a study in the Journal of Lipid Research investigating several HDL metrics, to determine how this lipid correlates with CVD risk in CKD patients.
The researchers examined two cohorts of CKD patients: 92 from the Clinical Phenotyping and Resource Biobank Core, 46 with incident CVD and 46 without, and 91 from the Chronic Renal Insufficiency Cohort, 34 with incident CVD and 57 without. In the baseline samples from these patients, they compared levels of HDL cholesterol, cholesterol efflux capacity and concentrations of HDL particles of sizes ranging from extra-small to extra-large. In both cohorts, levels of most of these metrics were not different in CKD patients with or without incident CVD; however, levels of medium-sized HDL — but not other sizes — were lower in CKD patients with incident CVD. This indicates that medium-sized HDL particles might have a cardioprotective function.
Different-sized HDL particles contain different combinations of proteins, the team noted, and medium-sized particles may house proteins with more protective functions, such as PON1, an enzyme that they previously showed was associated with incident CVD in CKD subjects when at low levels.
According to Shao, their current study “demonstrated that reduced levels of medium HDL particles, but not other sized HDL particles, can predict future CVD events in CKD patients. In addition to being an accurate marker to predict future CVD events, it raises the possibility that therapies that augment levels of medium HDL particles might be important to prevent CVD in CKD subjects.”
Overall, Shao’s group investigated why CKD patients are at increased risk for CVD, given the severity of both diseases. “If kidney disease worsens, waste can build up to high levels in your blood and make you feel sick, and it may eventually lead to kidney failure,” Shao wrote in an email. Moreover, “heart disease is the primary cause of death for all people with CKD.” This investigation into the relationship between the kidneys and the heart may improve efforts to treat and prevent CVD in CKD patients. “Medium-sized HDL can be an attractive marker,” Shao wrote, “that can be clinically useful to predict future events as well as potentially serving as a therapeutic target.”

Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

How scientists identified a new neuromuscular disease
NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.